TY - CHAP A1 - Hessel, Franz T1 - Die Machbarkeit der Erhebung der Zahlungsbereitschaft über soziale Netzwerke am Beispiel von Darmkrebs-Screening T2 - Jahrestagung der Deutschen Gesellschaft für Gesundheitsökonomie (DGGÖ), Essen N2 - Zielsetzung: Die Zielsetzung der vorliegenden Studie war es, die Machbarkeit der Erhebung der Zahlungsbereitschaft über soziale Netzwerke, hier Facebook, am Beispiel des Darmkrebs-Screenings zu untersuchen. Bei dem beschriebenen neuen diagnostischen Test handelt es sich um den neuartigen molekularen Bluttest Septin9, der im Vergleich zu standardmässig für Routinescreening auf Darmkrebs eingesetzten Test auf okkultes Blut im Stuhl (FOBT) eine bessere Performance, eine bessere Handhabbarkeit und eine bessere Compliance von Patienten und Ärzten aufweist. Methodik: Es wurden Informationen zum Krankheitsbild und den alternativen Screeningmethoden für Darmkrebs gegeben. Die Zahlungsbereitschaft wurde in binären Kategorien (<100 oder >100 EUR) und als Höchstbetrag erfasst. Die weiteren Parameter wie Alter, Geschlecht, Versicherten- und Einkommensstatus, Ernährung, Kontakt mit Krebserkrankungen und gesundheitsbewusstes Verhalten (Alkohol, Rauchen) wurden in Kategorien erfasst. Die Befragung wurde von sechs Facebook-Accounts an insgesamt rund 500 Nutzer des sozialen Netzwerks mit der Möglichkeit der weiteren Distribution versandt. Die Beantwortung eines Kern-Teils der Fragen wurde als Bedingung für die anonyme Einsendung über einen Dropbox-Link vorausgesetzt. Der Rücklaufzeitraum betrug 14 Tage. Ergebnisse: Es gingen 123 komplett ausgefüllte Fragebögen ein. Die Teilnehmer waren im Schnitt 24,2 Jahre und verdienen zu 94 % weniger als 1500 EUR monatlich. 27 % der Teilnehmer sind privat versichert. 68% gaben an in der Familie von Krebs betroffen zu sein und 36 %, dass sie sich der Gefahr von Darmkrebs bewusst sind. Die Angaben zum wichtigsten Attribut eines Screening-Tests verteilten sich folgendermaßen: 69 % Testgenauigkeit, 14 % Handling, 11 % Preis und 6% Schnelligkeit des Ergebnisses. 24 % gaben eine Zahlungsbereitschaft von weniger als 100 EUR an (Mittelwert 34 EUR), 76 % waren bereit mehr als 100 EUR zu bezahlen. Die durchschnittliche Zahlungsbereitschaft lag bei 271 EUR. Ein höheres Einkommen, eine Krebserkrankung in der Familie und ein Privatversichertenstatus waren mit einer höheren Zahlungsbereitschaft korreliert. Schlussfolgerung: Eine Messung der Zahlungsbereitschaft sowie weiterer die Patientenpräferenzen beschreibender Variablen ist über soziale Netzwerke mit vergleichsweise geringem Aufwand möglich. Vorteile liegen in der Freiwilligkeit und der Anonymität der Erhebung, wodurch direkte, nicht standardisierte Beeinflussungsmöglichkeiten während der Befragung als Bias wegfallen. Nachteile liegen in der sicherlich starken Selektion der Zielgruppe, was zu einer Einschränkung der Anwendbarkeit der Methode führt. KW - Soziale Netzwerke KW - Darmkrebsvorsorge Y1 - 2013 N1 - Volltext aus urheberrechtlichen Gründen nicht verfügbar. Fulltext due to copyright not available. ER - TY - GEN A1 - Hessel, Franz T1 - Gesundheitsmanagement N2 - Keine Angabe No details KW - Gesundheitsmanagement Y1 - 2012 N1 - Volltext aus urheberrechtlichen Gründen nicht verfügbar. Fulltext due to copyright not available. ER - TY - CHAP A1 - Hessel, Franz A1 - Biermann, Janine A1 - Kerkemeyer, Linda A1 - Korff, Lasse A1 - Mostardt, Sarah A1 - Neumann, Anja ED - Wasem, Jürgen T1 - Arzneimittelversorgung T2 - Medizinmanagement: Grundlagen und Praxis N2 - Keine Angabe - No details KW - Medizinische Einrichtung KW - Arzneimittelversorgung Y1 - 2013 N1 - Volltext aus urheberrechtlichen Gründen nicht verfügbar. Fulltext due to copyright not available. SP - 355 EP - 391 PB - Medizinisch Wissenschaftliche Verlagsgesellschaft CY - Berlin ER - TY - JOUR A1 - Hessel, Franz T1 - Personalized Medicines: worth the Effort and Investment? JF - Pharmaceutical Executive N2 - Prof. Dr. Franz Hessel questions whether personalized medicine and companion diagnostics are actually enhancing the drug development process. KW - Personalized Medicine KW - Drug Development Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:0298-opus4-5479 VL - 11 SP - 2 EP - 6 ER - TY - CHAP A1 - Hessel, Franz T1 - The relevance of the analytic validity of genetic tests in personalized medicine technologies for reimbursement decision making in Germany T2 - EACME Annual Conference, Bochum N2 - Keine Angabe - No details KW - Personalized Medicine KW - Germany Y1 - 2013 N1 - Volltext aus urheberrechtlichen Gründen nicht verfügbar. Fulltext due to copyright not available. ER - TY - CHAP A1 - Hessel, Franz T1 - Developing personalized medicine drugs: incentives for pharmaceutical companies T2 - EACME Annual Conference, Bochum N2 - Objectives: Stratification of oncology drug therapy by genetic marker diagnostics can reveal additional patient benefit but also might influence the development process of drug manufacturers. The objective of this study is to identify and describe the most important incentives for pharmaceutical companies to develop personalized medicine drugs. Methods: To describe the main factors influencing the decision making process in the development of personalized medicine drugs we designed a qualitative systemdynamic model. The main factors influencing the process and their priority ranking were determined by systematic literature search, structured expert interviews with pharmaceutical companies, test manufacturers and other key stakeholders such as regulatory bodies, reimbursement decision makers and payers. The model was build with the Consideo iModeler software package. Results: In contrast to small companies big international companies constantly look for suitable companion diagnostic tests to select subgroups of high responder. The most important key factor for market success is the extent of clinical efficacy in comparison with competitors respectively the current treatment standard. Stratification of patient populations according to treatment response or frequency of adverse events using biomarker is regarded to increase clinical efficacy of the target indication. The test performance is important due to unsolved safety issues although not regarded as crucial for the success of the drug. In contrast to other stakeholders pharmaceutical companies did not consider personalized medicine to relevantly decrease development costs or marketing efforts respectively to increase the price potential for new drugs. A low prevalence of the remaining patient population after testing is not irrelevant but it is not seen as a factor which might lead to a stop of the development of a new drug by pharmaceutical companies. Conclusions: Genetic stratification is seen as a breakthrough in cancer therapy by pharmaceutical companies and physicians. Due to the current need for improvement of approval and reimbursement processes for personalized medicine approaches in oncology especially in Europe future sales are more difficult to predict. KW - Personalized Medicine KW - Pharmaceutical Companies Y1 - 2013 N1 - Volltext aus urheberrechtlichen Gründen nicht verfügbar. Fulltext due to copyright not available. ER - TY - JOUR A1 - Moock, Jörn A1 - Hessel, Franz A1 - Ziegeler, Diana A1 - Kubiak, Thomas A1 - Kohlmann, Thomas T1 - Development and Validation of the Insulin Treatment Experience Questionnaire (ITEQ) JF - The Patient N2 - Objectives: To develop and psychometrically evaluate a domain-specific questionnaire to assess subtle but clinically relevant differences in treatment experiences and satisfaction over a wide range of currently available insulin therapy regimens. The study focussed on patients with type 2 diabetes mellitus and placed particular attention on the impact of different forms of insulin therapy on diabetes self-management. Methods: The development of the Insulin Treatment Experience Questionnaire (ITEQ) was conducted in three steps: (i) a qualitative phase to generate relevant items and identify relevant domains; (ii) a pilot study to reduce the number of generated items; and (iii) a validation study to assess major psychometric properties of the final ITEQ version. Results: The final version of the questionnaire comprised 28 items with the subscales ‘leisure activities’ (four items), ‘psychological barriers’ (two items), ‘handling’ (five items), ‘diabetes control’ (six items), ‘dependence’ (five items), ‘weight control’ (three items), ‘sleep’ (two items), and one further item assessing general treatment satisfaction. The subscales’ internal consistencies (Cronbach’s alpha) ranged from 0.52 to 0.83. Motivated by the homogenous structure of inter-scale-correlations (range 0.10–0.46), a summary composite score was calculated (alpha = 0.86). Construct validity showed statistically significant correlations with other scales (ITEQ vs the Problem Areas in Diabetes [PAID] questionnaire total score −0.60, ITEQ vs the Diabetes Treatment Satisfaction Questionnaire [DTSQ] total score 0.52). Conclusion: The newly developed ITEQ displayed satisfactory to good psychometric properties, thereby allowing the assessment of everyday life experience and treatment satisfaction in patients with insulin-treated type 2 diabetes. Additional research is needed to assess test-retest reliability and sensitivity to change. KW - Diabetis Self-Management KW - Diabetis Mellitus Y1 - 2010 N1 - Online: https://www.researchgate.net/publication/233507832_Development_and_Testing_of_the_Insulin_Treatment_Experience_Questionnaire_ITEQ VL - 3 IS - 1 SP - 45 EP - 58 ER - TY - JOUR A1 - Hessel, Franz A1 - Bramlage, Peter A1 - Wasem, Jürgen A1 - Mitzner, Steffen R. T1 - Cost effectiveness of the artifical liver support system MARS in patients with acute-on-chronic liver failure JF - European Journal of Gastroenterology & Hepatology N2 - For patients with an acute exacerbation of chronic liver failure (ACLF), the molecular adsorbent recirculating system (MARS) can result in a prolongation of life, but data on costs and cost-effectiveness are lacking. A health economic evaluation of a prospective controlled cohort trial in patients with ACLF not eligible for liver transplantation with 3 years follow-up and consecutive modelling of long-term costs, outcomes and cost-effectiveness was conducted. Costs were calculated from the perspective of the German health-care system. One hundred and forty-nine patients with ACLF were included of which 67 (44.9%) were treated with MARS and 82 (55.1%) assigned to the control group. Mean survival was 692 days in MARS-treated patients (33% survival after 3 years) and 453 days in control patients (15% after 3 years, logrank P = 0.022). MARS patients gained 0.66 [95% confidence interval (CI): -0.12 to 1.46] life years (LYs), determined by the bootstrap method. The mean cost difference was 19.835 euro (95% CI: 13.308-25.429) with 35639 euro for MARS-treated patients and 15804 euro for controls. Incremental costs per LY gained were 29.985 euro (95% CI: 9.441-321.761) and 43.040 euro (95% CI: 13.551-461.856) per quality-adjusted LY gained. There is an acceptable cost-effectiveness of MARS, compared with other medical technologies presently reimbursed. Randomized controlled trials with sufficient sample size are necessary before a final recommendation for MARS can be given. KW - Health Economics KW - Cost Benefit Analysis Y1 - 2010 N1 - Online: https://www.researchgate.net/publication/26830926_Cost-effectiveness_of_the_artificial_liver_support_system_MARS_in_patients_with_acute-on-chronic_liver_failure VL - 22 IS - 2 SP - 213 EP - 220 ER - TY - JOUR A1 - Reinhold, Thomas A1 - Brüggenjürgen, Bernd A1 - Schlander, Michael A1 - Rosenfeld, Stephanie A1 - Hessel, Franz A1 - Willich, Stefan N. T1 - Economic analysis based on multinational studies: methods for adapting findings to national contexts JF - Journal of Public Health N2 - Background: Health economic parameters are increasingly considered as variables in health care decisions, but decision makers are interested in country-specific evaluations. However, a large number of studies are performed in foreign countries or in a multinational setting, which limits the transferability to a single nation’s context. Objective: The present analysis summarises several of the most common international methods for generating health economic analyses based on clinical studies from different settings. Methods: A narrative literature review was performed to identify potential reasons for limited transferability of health economic evaluation results from one country to another. Based on these results, we searched the methodological literature for analytic approaches to handle the restrictions. Additionally we describe the possibility of transferring foreign economic study results to the country of interest by matching trial data with routine data of national databases. Results: The main factors for limited transferability of health economic findings were found in country-specific differences in resource consumption and the resulting costs. These differences are affected by a number of influencing cofactors (demography, epidemiology and individual patient’s factors) and the overall health care system structures (e.g. payment systems, health provider incentives). However, despite the limitations country-specific health economic assessments could be realised using the pooled/split analyses approach, some statistical approaches and modelling approaches. Conclusion: A variety of methods for identifying and adjusting country-specific differences in costs, effects and cost-effectiveness was established during the past decades. Multinational studies will continue to play a crucial role in the evaluation of cost-effectiveness at national levels. It seems likely that the growing interest in multinational studies will lead to continued developments in adaptation methods. KW - International Adaption KW - Cost-Effectiveness KW - Economic Evaluation Y1 - 2010 N1 - Online: https://www.ssoar.info/ssoar/handle/document/20369 VL - 18 IS - 4 SP - 327 EP - 335 ER - TY - GEN A1 - Hessel, Franz T1 - Knorpelzellentransplantation aus Sicht der Gesundheitsökonomie und Versorgungsforschung N2 - Keine Angabe No details KW - Transplantation KW - Gesundheitsökonomie KW - Versorgungsforschung Y1 - 2012 N1 - Volltext aus urheberrechtlichen Gründen nicht verfügbar. Fulltext due to copyright not available. ER -